Imatinib Mesylate News and Research

RSS
Imatinib mesylate (also called Gleevec® or STI571) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of some forms of adult and pediatric chronic myelogenous leukemia (CML), and for the treatment of a rare form of cancer called gastrointestinal stromal tumor (GIST).

With CML, imatinib works by blocking an abnormal enzyme characteristic of the disease. In GIST, imatinib blocks a different abnormal enzyme found on the tumor cells.

Imatinib is the first approved drug to directly turn off the signal of a protein known to cause a cancer. Other molecular-targeting drugs previously approved by the FDA interfere with proteins associated with other cancers, but not with proteins that directly cause the disease.

Imatinib is being investigated for its effectiveness against other kinds of cancer, as well, including acute lymphocytic leukemia and hypereosinophilic syndrome (HES).
Pfizer's new pipeline shows growth and diversity in research and development

Pfizer's new pipeline shows growth and diversity in research and development

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Pfizer reports final results from randomized Phase 3 trial of Sutent

Pfizer reports final results from randomized Phase 3 trial of Sutent

Preliminary studies show cancer vaccine may reduce tumor cells in CML patients

Preliminary studies show cancer vaccine may reduce tumor cells in CML patients

Update on new clinical developments and other initiatives related to Ceplene

Update on new clinical developments and other initiatives related to Ceplene

ChemGenex Pharmaceuticals and Hospira enter into exclusive agreement

ChemGenex Pharmaceuticals and Hospira enter into exclusive agreement

Pfizer to present study findings from its expanded breast cancer portfolio

Pfizer to present study findings from its expanded breast cancer portfolio

New data demonstrating the strength of Novartis' hematology portfolio to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

FDA grants full approval for Sprycel (dasatinib) for chronic myeloid leukemia

FDA grants full approval for Sprycel (dasatinib) for chronic myeloid leukemia

Genetic signature may predict patient response to GIST therapy

Genetic signature may predict patient response to GIST therapy

Discovery of genetic pattern that may predict response to Gleevec in GIST

Discovery of genetic pattern that may predict response to Gleevec in GIST

Therapeutic effect of imatinib improved with addition of chloroquine

Therapeutic effect of imatinib improved with addition of chloroquine

Enhancing the effects of imatinib mesylate used to treat chronic myeloid leukemia

Enhancing the effects of imatinib mesylate used to treat chronic myeloid leukemia

Data suggesting that omacetaxine can eradicate leukemic stem cells may offer a breakthrough for CML

Data suggesting that omacetaxine can eradicate leukemic stem cells may offer a breakthrough for CML

Gleevec reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors

Gleevec reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors

FDA approves Gleevec (imatinib mesylate) to prevent gastrointestinal stromal tumor

FDA approves Gleevec (imatinib mesylate) to prevent gastrointestinal stromal tumor

When less is more: Brief inhibition of cancer target is effective and less toxic

When less is more: Brief inhibition of cancer target is effective and less toxic